Literature DB >> 10688843

A study of the coregulation and tissue specificity of XG and MIC2 gene expression in eukaryotic cells.

C Fouchet1, P Gane, M Huet, M Fellous, P Rouger, G Banting, J P Cartron, C Lopez.   

Abstract

CD99, the product of the MIC2 gene, exhibits an erythroid-specific quantitative polymorphism coregulated with the polymorphism of the XG blood group gene. As a preliminary study of this phenomenon, human XG and CD99 recombinant proteins were expressed in murine RAG cells and analyzed by flow cytometry. Both proteins were expressed independently and at a similar level in single and double transfectants. Immunoprecipitation and Western blot analysis, using the murine monoclonal antibodies NBL-1 and 12E7, revealed species of 26 kd (XG) and 32 kd (CD99), respectively. A putative 28-kd intracellular precursor of CD99 was also detected, as was a 26-kd species after neuraminidase treatment of CD99-expressing cells. No evidence of association or complex formation between XG and CD99 proteins could be proven, either on transfected RAG cells or on human erythrocytes. These results were confirmed using somatic hybrids between single transfectants. These findings suggest that the phenotypic relationship between XG and CD99 is mostly regulated at the transcriptional level, but they do not formally exclude some posttranscriptional effect. Studies on the tissue specificity of XG expression showed that surface expression of the XG protein could not be restored in somatic hybrids between B-lymphoblastoid cell lines from Xg(a+) persons and fibroblasts (RAG) or erythroid (MEL) cells. RT-PCR analysis of the transcripts revealed the existence of an XG mRNA in each cell line, suggesting that the tissue-specific regulation of cell surface XG expression occurs either at a quantitative transcriptional level or is a posttranscriptional event. By Northern blot analysis, XG transcripts were detected in erythroid tissues and several nonerythroid tissues. (Blood. 2000;95:1819-1826)

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10688843

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  7 in total

1.  The molecular genetic background leading to the formation of the human erythroid-specific Xga/CD99 blood groups.

Authors:  Chih-Chun Yeh; Ching-Jin Chang; Yuh-Ching Twu; Chen-Chung Chu; Bi-Shan Liu; Ji-Ting Huang; Shu-Ting Hung; Yung-Syu Chan; Yi-Jui Tsai; Sheng-Wei Lin; Marie Lin; Lung-Chih Yu
Journal:  Blood Adv       Date:  2018-08-14

2.  CD99 acts as an oncosuppressor in osteosarcoma.

Authors:  Maria Cristina Manara; Ghislaine Bernard; Pier-Luigi Lollini; Patrizia Nanni; Monia Zuntini; Lorena Landuzzi; Stefania Benini; Giovanna Lattanzi; Marika Sciandra; Massimo Serra; Mario Paolo Colombo; Alain Bernard; Piero Picci; Katia Scotlandi
Journal:  Mol Biol Cell       Date:  2006-01-18       Impact factor: 4.138

3.  When recombinant proteins can replace rare red cells in immunohematology workups.

Authors:  Willy A Flegel; Kshitij Srivastava
Journal:  Transfusion       Date:  2021-05-31       Impact factor: 3.337

Review 4.  CD99: A Cell Surface Protein with an Oncojanus Role in Tumors.

Authors:  Maria Cristina Manara; Michela Pasello; Katia Scotlandi
Journal:  Genes (Basel)       Date:  2018-03-13       Impact factor: 4.096

Review 5.  CD99 at the crossroads of physiology and pathology.

Authors:  Michela Pasello; Maria Cristina Manara; Katia Scotlandi
Journal:  J Cell Commun Signal       Date:  2018-01-06       Impact factor: 5.782

6.  Identification of cell surface proteins as potential immunotherapy targets in 12 pediatric cancers.

Authors:  Rimas J Orentas; James J Yang; Xinyu Wen; Jun S Wei; Crystal L Mackall; Javed Khan
Journal:  Front Oncol       Date:  2012-12-17       Impact factor: 6.244

Review 7.  Sex chromosome loss and the pseudoautosomal region genes in hematological malignancies.

Authors:  Stephanie Weng; Samuel A Stoner; Dong-Er Zhang
Journal:  Oncotarget       Date:  2016-11-01
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.